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FibronectinFibrillins form multifunctional microﬁbrils in most connective tissues. Deﬁciencies in ﬁbrillin
assembly can result in ﬁbrillinopathies, such as Marfan syndrome. We demonstrate the presence
of heparin/heparan sulfate binding sites in ﬁbrillin-2 and -3. Multimerization of all three ﬁbrillins
drastically increased the apparent afﬁnity of their interaction with heparin/heparan sulfate. Surpris-
ingly, contrary to other reports heparin/heparan sulfate strongly inhibited homo- and heterotypic
N-to-C-terminal ﬁbrillin interactions. These data suggest that heparin/heparan sulfate controls
the formation of microﬁbrils at the bead interaction stage.
Structured summary of protein interaction:
rFBN1-N binds to rFBN1-C by solid phase assay (View interaction)
rFBN1-N binds to rFBN2-C by solid phase assay (View interaction)
rFBN2-N binds to rFBN1-C by solid phase assay (View interaction)
rFBN2-N binds to rFBN2-C by solid phase assay (View interaction)
Fibronectin binds to rFBN2-C by solid phase assay (View interaction)
Fibronectin binds to rFBN2-N by solid phase assay (View interaction)
Fibronectin binds to rFBN1-N by solid phase assay (View interaction)
Fibronectin binds to rFBN1-C by solid phase assay (View interaction)
Fibronectin binds to rFBN3-C by solid phase assay (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction component assemblies, termed microﬁbrils [2]. ExtractedThree extracellular glycoproteins, ﬁbrillin-1, -2 and -3
constitute the ﬁbrillin family. Each member of this family is char-
acterized by a modular organization composed primarily of
calcium-binding epidermal growth factor-like (cbEGF) domains
and transforming growth factor (TGF)-b binding domains (TB)
[1]. Fibrillins are the main integral components of multi-microﬁbrils display a characteristic ‘‘bead-on-a-string’’ structure
[3]. Microﬁbrils fulﬁll a number of crucial physiological functions
in the cardiovascular system, bones, eyes, skin and other tissues
[4]. They act as a scaffold in elastic ﬁber formation, as stress-bear-
ing entities, and as reservoirs for growth factors of the TGF-b
superfamily [5–7]. Deﬁciencies in microﬁbrils have devastating
consequences on tissue function and integrity resulting in severe
connective tissue disorders [8]. Fibrillin-1 mutations result for
example in Marfan syndrome, autosomal dominant Weill–Marche-
sani syndrome and stiff skin syndrome, whereas ﬁbrillin-2 muta-
tions cause congenital contractural arachnodactyly [9–12].
Despite recent advances, the complete mechanism of ﬁbrillin
assembly into microﬁbrils is still poorly deﬁned. We previously
demonstrated that the recombinant C-terminal half of ﬁbrillin-1
multimerizes in a cell-associated fashion [13]. The multimers have
a characteristic bead shape with 8–12 peripheral arms, closely
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multimerization of the ﬁbrillin-1 C-terminus increases the appar-
ent afﬁnity to its N-terminus [13]. Elongation occurs through ﬁbril-
lin N-to-C terminal interactions in a polarized manner [14,15].
Several molecules have been implicated in microﬁbril assembly
including heparan sulfate and ﬁbronectin [16–19].
Proteoglycans and glycosaminoglycans have been localized to
microﬁbrils and some have been implicated in microﬁbril assem-
bly. The dermatan sulfate-containing biglycan interacts with
microﬁbrils, whereas decorin can form a ternary complex with
ﬁbrillin-1 and microﬁbril-associated glycoprotein-1 (MAGP-1)
[20]. The heparan sulfate-containing proteoglycan perlecan in
basement membranes directly interacts with ﬁbrillin-1 and colo-
calizes with microﬁbrils at basement membrane zones with poten-
tial implications on microﬁbril assembly in these regions [21].
Kielty et al. have demonstrated that microﬁbril integrity is dis-
rupted by treatment with chrondroitinase-4,6-sulfate lyases [22].
The most studied glycosaminoglycan in microﬁbril assembly is
heparin/heparan sulfate. Heparan sulfate consists of repeats of sul-
fated disaccharide units of glucuronic acid and N-acetylglucosa-
mine, and each unit can be modiﬁed by N- and O-sulfation as
well as by uronate epimerization [23]. These modiﬁcations oftenFig. 1. Fibrillin interactions with heparin and heparan sulfate. (A) A schematic drawin
indicates previously identiﬁed heparin-binding sites (‘‘H’’) as well as N-to-C-terminal (
illustrates the ﬁbrillin fragments used in this study. The color and symbol of each fragm
ﬁrst heparin-binding site located in the N-terminal propeptide of ﬁbrillin-1 is not includ
domains corresponding to the schematic ﬁbrillin drawing on top. (B) Shown is a represen
(open symbols) used as a control, were immobilized. Serial dilutions of recombinant ﬁb
Soluble recombinant ﬁbrillin fragments were added to immobilized heparan sulfate-BSA
assembly states and were not gel-ﬁltrated. Data sets represent means of duplicates; stan
was subtracted from all values.occur in clusters resulting in sulfated domains. The degree of
modiﬁcation regulates protein interaction to heparan sulfate. For
example, ﬁbrillin-1 only interacts with highly sulfated heparan sul-
fate [17]. Heparan sulfate is not found as a free glycosaminoglycan
in tissues. In its physiological state it is covalently linked to a num-
ber of core proteins to form various proteoglycans including cell
surface located syndecans and glypicans or matrix located perlec-
an, agrin, collagen type XV or type XVIII [23]. Heparin is structur-
ally very similar to heparan sulfate and is frequently used
experimentally as a cost-effective substitute for heparan sulfate
[23].
Fibrillin-1 interaction domains with heparin/heparan sulfate
have been described in seven regions of the protein (see Fig. 1A)
[17,19,24–26]. A heparin/heparan sulfate interaction site in ﬁbril-
lin-2 has been localized to cbEGF7-TB3 [19]. The ﬁbrillin-1 hepa-
rin/heparan sulfate interaction sites were shown to be speciﬁc
for heparin/heparan sulfate and could not interact with other gly-
cosaminoglycans [17]. Knowledge of heparin/heparan sulfate
interactions with ﬁbrillin-2 is still rudimentary, and it is not known
if ﬁbrillin-3 also interacts with this glycosaminoglycan. Heparin/
heparan sulfate may regulate the composition of microﬁbrils as it
inhibits in vitro the interactions of tropoelastin or MAGP-1 withg of recombinant ﬁbrillin-1, -2 and -3 is shown on top. The ‘‘Interactions’’ panel
‘‘NC’’) ﬁbrillin interaction sites in ﬁbrillin-1. The ‘‘Recombinant Fragments’’ panel
ent corresponds to the respective fragment binding proﬁle in B and C. Note that the
ed in the recombinant fragments. The ‘‘Domains’’ panel indicates the names of the
tation of a typical solid phase binding assay. Heparin-BSA (closed symbols) and BSA
rillin fragments were added as soluble ligands at the indicated concentrations. (C)
. For B and C, all C-terminal fragment preparations consisted of a mixture of ﬁbrillin
dard deviations are indicated. Non-speciﬁc interaction with BSA (OD492nm = 0.1–0.2)
2892 L. Sabatier et al. / FEBS Letters 588 (2014) 2890–2897ﬁbrillin-1 [24]. Heparin/heparan sulfate interactions with ﬁbrillins
play a critical role in ﬁbrillin network assembly as it inhibits ﬁbril-
lin-1 ﬁber formation when added exogenously to mesenchymal
cell cultures [17,19]. However, the exact role of heparin/heparan
sulfate in the biogenesis of microﬁbrils is not well deﬁned.
2. Materials and methods
2.1. Antibodies
The generation of rabbit polyclonal antibodies against the N-
and C-terminal halves of ﬁbrillin-1 (anti-rFBN1-N, anti-rFBN1-C)
[17,21], ﬁbrillin-2 (anti-rFBN2-N, anti-rFBN2-C) [15], and ﬁbril-
lin-3 (anti-rFBN3-C) [16] was described previously. The monoclo-
nal anti-ﬁbronectin antibody (anti-FN clone 15) was purchased
(Sigma; #F7387). Secondary antibodies labeled with ﬂuorescent
dyes were purchased from Jackson ImmunoResearch Laboratories.
2.2. Proteins and glycosaminoglycans
The production and puriﬁcation of the N- and C-terminal halves
of ﬁbrillin-1 (rFBN1-N, rFBN1-C) [27], ﬁbrillin-2 (rFBN2-N, rFBN2-
C) [15], and ﬁbrillin-3 (rFBN3-C) [16] was described previously.
Puriﬁcation of the N-terminal half of ﬁbrillin-3 was intensively
attempted, but remained unsuccessful due to extreme proteolytic
susceptibility. Puriﬁcation of the recombinant ﬁbrillin-1 fragments
rF18 and rF23 and of human plasma ﬁbronectin was previously
described [14,28,29]. Heparin from porcine intestinal mucosa
(Sigma; #H3393) was resuspended in 50 mM Tris–HCl, pH 7.4,
150 mM NaCl Tris-buffered saline (TBS) and dialyzed against the
same buffer. Heparin was also coupled to bovine serum albumin
(heparin–BSA) (Thermo Fisher Scientiﬁc; #BP1605) as described
[30]. The same procedure was used to couple heparan sulfate
(Sigma; #H7640) to BSA.
2.3. Cell culture conditions and heparin inhibition
Human skin ﬁbroblasts were isolated from foreskin after cir-
cumcision and cultivated under standard conditions in DMEM con-
taining 10% ﬁbronectin-depleted fetal calf serum. For inhibition,
heparin (0.25–1 mg/mL) and heparin-BSA (3.1–25 lg/mL) was
added at the time of cell seeding (7.5  104 cells/well) in eight-well
chamber slides. Cells were ﬁxed after 3 days and stained for ﬁbro-
nectin, ﬁbrillin-1 and ﬁbrillin-2 as described previously [16].
2.4. Solid phase and inhibition assay
Solid phase binding assays were performed as previously
described [15]. In brief, 10 lg/mL TBS of heparin-BSA and heparan
sulfate-BSA, ﬁbronectin, or ﬁbrillin were immobilized in 96-well
plates (Maxisorp). Blocking was performed with 5% non-fat milk
in TBS including 2 mM CaCl2. All washing steps were performed
with 0.05% Tween-20 in TBS (TBST). Recombinant ﬁbrillin frag-
ments were diluted in 2% non-fat milk in TBS including 2 mM CaCl2
(binding buffer) and incubated with the immobilized protein for
2 h. For inhibition experiments, constant concentrations (50 lg/
mL) of soluble ligands were added with various concentrations of
heparin in binding buffer. Primary antibody (1:1000 diluted) was
added for 1.5 h. Peroxidase-conjugated goat anti-rabbit antibody
(1:800 diluted) was incubated for 1.5 h followed by a color reaction.
2.5. Surface plasmon resonance spectroscopy
Surface plasmon resonance spectroscopy was performed with a
BiacoreX instrument (GE Healthcare). C1 sensor chips were usedwith heparin-BSA or ﬁbronectin immobilized by amine coupling
on one channel and BSA as a control immobilized on the second
channel. Real-time association and dissociation were monitored
in duplicates or triplicates by injecting proteins diluted at 0.1–
100 lg/mL in TBS/2 mM CaCl2, pH 7.4. Kinetic analyses were per-
formed using the BIAevaluation software by ﬁtting the association
and dissociation curves with a 1:1 binding model.
2.6. Gel ﬁltration chromatography
Multimers, intermediates and monomers of the recombinant C-
terminal halves of ﬁbrillin-1 (rFBN1-C), ﬁbrillin-2 (rFBN2-C) and
ﬁbrillin-3 (rFBN3-C) were separated by Superose 6 gel ﬁltration
chromatography (GE Healthcare; 100 mL column) as described
previously using 2.7 mg of recombinant proteins [13,16].
3. Results
3.1. Fibrillin-1, -2 and -3 interactions with heparin and heparan
sulfate
Previous studies have identiﬁed seven heparin/heparan sulfate
binding sites in human ﬁbrillin-1 and one in the central region of
human ﬁbrillin-2 [17,19,24,25]. To investigate if additional heparin
interaction sites exist in human ﬁbrillin-2 and whether ﬁbrillin-3
also interacts with heparin, solid phase binding assays were per-
formed with recombinant N- and C-terminal halves of ﬁbrillin-1
and -2 and with the C-terminal half of ﬁbrillin-3 (Fig. 1A and B).
Fibrillin-2 and -3 fragments bound heparin-BSA similar as ﬁbril-
lin-1 fragments. No signiﬁcant interaction between the ﬁbrillin
fragments and the BSA control was observed. We conclude that
one or more high afﬁnity heparin-binding sites exist in the ﬁbril-
lin-2 N- and C-terminal halves and in the ﬁbrillin-3 C-terminal
half.
Heparin and heparan sulfate are structurally very similar as
both macromolecules are composed of the same disaccharide
repeating unit [23]. Heparin is thus used here and in many other
studies as a cost-effective substitute for heparan sulfate, which is
found in tissues where ﬁbrillins are expressed [23]. Therefore, we
compared the interactions of the ﬁbrillins with heparin and hepa-
ran sulfate (Fig. 1B and C). Generally, all tested ﬁbrillin fragments
interacted with heparan sulfate-BSA. Fragment rFBN1-N typically
showed stronger interaction and rFBN2-C was characterized by
lower binding proﬁles with heparan sulfate as compared to
heparin.
3.2. Fibrillin multimerization regulates heparin interaction
We have shown that C-terminally mediated multimerization of
ﬁbrillin is important for the generation of high afﬁnity interaction
sites for ﬁbrillin-1 N-to-C-terminal self-interactions, and for inter-
actions with ﬁbronectin [13,16]. To investigate if multimerization
is required for the interaction with heparin, multimers, intermedi-
ates and monomers of rFBN1-C, rFBN2-C and rFBN3-C were sepa-
rated by gel ﬁltration chromatography and tested for interaction
with heparin-BSA (Fig. 2A). Multimers interacted strongly with
heparin-BSA, intermediates interacted moderately, and monomers
showed virtually no interactions in solid phase interaction assays.
As an important control, we veriﬁed that the antibodies used to
detect the bound ligands did not show increased afﬁnity for the
multimeric versus monomeric form of each ﬁbrillin (Fig. 2B). We
then compared the heparin interaction of the multimeric C-termi-
nal ﬁbrillin-1 with previously identiﬁed heparin-binding sites in
the N-terminus mediated by monomeric fragments rF18
and rF23 (Fig. 2C) [13,17,24,25]. Again, relative to multimeric
Fig. 2. Multimerization of the ﬁbrillin C-terminal halves drastically increases the interaction with heparin. (A) Shown is a representative solid phase binding assay. Heparin-
BSA was immobilized and incubated with serial dilutions of soluble rFBN1-C, rFBN2-C and rFBN3-C multimers (open triangles), intermediates (open circles) or monomers
(open squares). Data sets represent means of duplicates. Standard deviations are indicated. (B) ELISA assay with immobilized rFBN1-C (left panel), rFBN2-C (middle panel),
and rFBN3-C (right panel) monomers (open squares) and multimers (open triangles). TBS without immobilized protein (closed circles) was used as a control. The respective
antisera were incubated with the ligands at the indicated dilutions. Error bars represent standard deviations of duplicate values. (C) Shown is a typical solid phase binding
assay. Heparin-BSA was immobilized and incubated with soluble ﬁbrillin-1 N-terminal monomeric fragments rF18 (closed triangles) and rF23 (closed circles). For
comparison, multimers (open triangles), intermediates (open circles) and monomers (open squares) of rFBN1-C were also included. Means of duplicate data sets are indicated
and background interaction with BSA (OD492nm = 0.1–0.2) was subtracted. Error bars represent standard deviations.
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Table 1
Binding parameters of soluble ﬁbrillin C-terminal halves with immobilized heparin analyzed by surface plasmon resonance spectroscopy. Mixtures represent puriﬁed protein
preparations including monomers, intermediates and multimers. Additional gel ﬁltration of the protein preparations separated monomers, intermediates and multimers.
Fragment KD (nM) v2 ka (M1s1) kd (s1)
rFBN1-C Mixture 1.02 (±0.65) 4.19 (±1.65) 7.36 (±1.86)  105 7.50 (±2.11)  104
Monomers 16.63 (±5.92) 1.66 (±0.45) 3.36 (±0.96)  104 4.47 (±0.64)  104
Intermediates 2.68 (±0.42) 1.82 (±0.11) 1.43 (±0.14)  105 4.33 (±0.98)  104
Multimers 0.12 (±0.03) 2.43 (±0.26) 4.35 (±0.26)  105 5.35 (±0.43)  105
rFBN2-C Mixture 5.15 (±2.06) 4.82 (±2.55) 2.33 (±3.35)  105 1.20 (±0.57)  103
Monomers 34.39 (±10.31) 4.23 (±0.87) 3.27 (±0.25)  104 1.12 (±0.29)  103
Intermediates 19.71 (±6.02) 4.99 (±0.90) 7.51 (±1.47)  104 1.48 (±0.21)  103
Multimers 1.37 (±0.85) 5.48 (±2.16) 2.27 (±2.11)  105 3.11 (±1.96)  104
rFBN3-C Mixture 0.82 (±0.32) 3.74 (±1.85) 6.69 (±2.94)  105 5.48 (±1.23)  104
Monomers 38.78 (±15.50) 1.72 (±0.23) 2.63 (±0.60)  104 1.02 (±0.30)  103
Intermediates 0.35 (±0.10) 4.71 (±2.70) 3.34 (±0.50)  105 1.17 (±0.41)  104
Multimers 0.19 (±0.05) 3.34 (±1.59) 3.38 (±0.84)  106 6.42 (±1.58)  104
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least two magnitudes weaker with heparin. It is important to
mention that these binding experiments were optimized for the
interaction of multimeric rFBN1-C with heparin. Extended assay
times show heparin/heparan sulfate binding of rF18 and rF23 as
reported previously, and as expected from other studies
[17,24,25]. These experiments demonstrate that multimerization
of all three ﬁbrillins drastically increases their apparent afﬁnity
for heparin.
To quantify the afﬁnities of multimeric, intermediate and
monomeric ﬁbrillin C-termini for heparin, we employed surface
plasmon resonance spectroscopy (Table 1; Suppl. Fig. 1). Multimers
of rFBN1-C, rFBN2-C and rFBN3-C showed dissociation constants in
the low nanomolar and sub-nanomolar range, between KD = 0.12–
1.37 nM, demonstrating very high afﬁnity for heparin. As expected
from the solid phase assays, monomers showed signiﬁcantly lower
afﬁnities for heparin with dissociation constants between 17 and
39 nM, and intermediates were characterized with dissociation
constants between those of multimers and monomers. Differences
in the monomer interaction with heparin between solid phase
assays (virtually no interaction) and surface plasmon resonance
spectroscopy likely originate from the different immobilization
methods (adsorption versus amine coupling).
To compare these ﬁndings with the afﬁnities of rFBN-C-ﬁbro-
nectin interactions, which are also dependent on ﬁbrillin multi-
merization [16], we determined their dissociation constants by
surface plasmon resonance spectroscopy (Table 2). As expected
from the previous study, multimers of rFBN1-C, rFBN2-C and
rFBN3-C interacted with ﬁbronectin about 5–7 times more
strongly (KD  12–16 nM) than their respective monomers
(KD  55–96 nM). Compared to the interactions with heparin, the
ﬁbrillin–ﬁbronectin interactions were characterized by lower
afﬁnities of 1–2 magnitudes.Table 2
Dissociation constants of soluble monomeric and multimeric ﬁbrillin C-terminal
halves with immobilized ﬁbronectin determined by surface plasmon resonance
spectroscopy.
Fragment KD (nM)a
rFBN1-C Monomers 55.34 (±1.82)
Multimers 11.87 (±2.14)
rFBN2-C Monomers 84.75 (±5.20)
Multimers 16.28 (±3.76)
rFBN3-C Monomers 95.51 (±9.67)
Multimers 12.83 (±3.18)
a Closeness ﬁt error parameter v2 is from 0.86 to 4.72.3.3. Heparin inhibits ﬁbrillin homo- and heterotypic interactions
Fibrillin-1 forms homotypic interactions between its N- and C-
terminus and forms heterotypic interactions with ﬁbrillin-2 [15].
Fibrillin-1 and -2 can co-polymerize in microﬁbrils [31]. To
investigate whether heparin functionally interferes with the
ﬁbrillin N-to-C-terminal interactions, we tested its capacity to
inhibit ﬁbrillin homo- and heterotypic interactions (Fig. 3A).
Heparin efﬁciently inhibited both, homotypic and heterotypic
interactions of rFBN1-C and rFBN2-C with rFBN1-N and rFBN2-N,
suggesting that heparin/heparan sulfate plays a regulatory role at
the ﬁbrillin self-assembly stage. Heparin did not inhibit the inter-
action between rFBN1-C, rFBN2-C, rFBN3-C, or rFBN1-N and
rFBN2-N with ﬁbronectin (Fig. 3B). As expected, heparin did inhibit
the formation of ﬁbrillin-1 and -2 networks in cell culture, but did
not inhibit ﬁbronectin network formation (Fig. 3C). Similar inhibi-
tion proﬁles were observed with heparin-BSA (data not shown).
4. Discussion
We have previously shown that ﬁbrillin-1, -2 and -3 multimer-
ize through domains in their C-terminal halves, generating bead-
like structures that closely resemble the beads in microﬁbrils
[13,16]. This multimerization is a critical step in ﬁbrillin-1 assem-
bly, as it increases the apparent afﬁnity of the C-terminal region
(cbEGF41-43) to an N-terminal region (FUN-EGF3) [13,15,26,32].
These ﬁndings led to the hypothesis that C-terminally multimer-
ized and disulﬁde-bonded beads represent the initial microﬁbril
assembly unit [13]. Other interesting, but unexplained, ﬁndings
relevant to ﬁbrillin assembly demonstrated that addition of hepa-
rin and heparan sulfate dose-dependently inhibited microﬁbril
network formation in cell culture models [17,19]. Here, we show
data providing mechanistic explanations for the role of heparin/
heparan sulfate in microﬁbril assembly.
We determined that the C-terminal halves of ﬁbrillin-2 and -3
interact with heparin and heparan sulfate with similar afﬁnity as
the respective ﬁbrillin-1 region. Ritty et al. found that chemical
multimerization of a synthetic peptide representing the last 17 res-
idues of the processed ﬁbrillin-1 protein (Cys2715–Arg2731)
increases its afﬁnity to heparin [19]. In the present study, we show
with two independent methods that multimerization of the C-ter-
minal halves of all three ﬁbrillins dramatically increases the appar-
ent afﬁnity to heparin, compared to C-terminal monomers or
monomeric fragments from the N-terminal half. Quantiﬁcation of
heparin-binding strengths by surface plasmon resonance spectros-
copy clearly demonstrated that the apparent afﬁnities signiﬁcantly
increase, up to two hundred-fold, from monomers to multimers of
the C-terminal halves. The dissociation constants of multimers
Fig. 3. Heparin inhibits ﬁbrillin homo- and heterotypic interactions, but does not inhibit ﬁbrillin interaction with ﬁbronectin. (A and B) Shown are representative solid phase
inhibition experiments. (A) rFBN1-N and rFBN2-N, as indicated, were immobilized and incubated with constant concentrations (50 lg/mL) of rFBN1-C (black bars) or rFBN2-C
(grey bars) in the presence of increasing concentrations of heparin. The signal without heparin is set at 100%. Data sets represent means of quadruplicates for the rFBN1-N
coated and sextuplicates for the rFBN2-N coated experiment. Standard deviations are indicated. (B) Fibronectin was immobilized and incubated with constant concentrations
(50 lg/mL) of rFBN1-C (black bars), rFBN2-C (grey bars), or rFBN3-C (white bars) in the left panel, or rFBN1-N (black bars) or rFBN2-N (grey bars) in the right panel. Increasing
concentrations of heparin as indicated were added simultaneously with the soluble ligands. The signal without heparin is set at 100%. Data sets represent means of duplicates.
Standard deviations are indicated. (C) Indirect immunoﬂuorescence staining for ﬁbronectin (green, left panel), ﬁbrillin-1 (red, middle panel) and ﬁbrillin-2 (red, right panel)
after ﬁbroblasts were cultured for 3 days in the presence of a control volume of TBS (top row) or 0.25 mg/mL heparin (bottom row). Insets show higher magniﬁcations of
ﬁbrillin-1 and -2 staining.
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nanomolar range for ﬁbrillin-2. The KD values observed here for
the monomeric fractions of the C-terminal halves of all three ﬁbril-
lins were typically higher (lower afﬁnity) than the values observed
for smaller monomeric recombinant C-terminal subfragments of
ﬁbrillin-1 used by Cain et al. (16.6–38.8 nM versus 2.9–17.1 nM)
[25], whereas multimeric fragments displayed much lower KD val-
ues (in the latter study, multimers were excluded by gel-ﬁltration
chromatography). The reason for the discrepancy with the
monomeric fragments could stem from the different fragment
sizes used. It is possible that binding sites are more cryptic in a lar-
ger protein context (e.g. C-terminal halves) versus in the smaller
subfragments used by Cain et al. Different immobilization methods
(heparin-BSA vs. biotinylated heparin) could also have contributed
to these differences. Upon multimerization of the C-terminal
halves, the drastic increase in the apparent afﬁnity could occur
through the exposure of such cryptic interaction sites and/or
through the clustering of the individual binding sites (increase in
avidity). Upon multimerization of the full-length ﬁbrillin in cell
culture or in vivo, it is possible that all heparin-binding sites in
the analyzed monomeric fragments of the N-terminus will also
have their apparent afﬁnity for heparin/heparan sulfate raised.
However, based on the shape of the C-terminal multimers with
N-terminal ‘‘arms’’ loosely extending from the bead domain [13],
we expect the increase in their apparent afﬁnity to be much less
pronounced than that of the densely packed C-terminal ﬁbrillin
multimers. The propensity to aggregate currently prevents the
use of full-length ﬁbrillin to study these questions [15].
It was previously reported by Cain et al. that heparin does not
inhibit the interaction of an N-terminal fragment of ﬁbrillin-1
(PF1, comprising the region between the N-terminus and EGF4)
with aC-terminal fragment (PF13 spanning fromTB7 to the C-termi-
nus) [24,25]. Contrary to those results, in the present study we
clearly demonstrate that heparin can strongly and effectively inhibit
ﬁbrillin-1 and -2 homo- as well as heterotypic N-to-C-terminal
interactions. One obviousdifferencebetween the studies is that Cain
et al. usedmonomeric fragments,whereas the preparations of the C-
terminal halves contain signiﬁcant amounts of ordered multimersFig. 4. Model of microﬁbril assembly. At the time of secretion, ﬁbrillin propeptides are
(Step 2). Multimers interact with heparan sulfate proteoglycans on the cell surfac
multimerization (Step 3). Induction of focal adhesion formation and tension hypothetica
C-terminal self-interaction of the beads (Step 4). Transfer of nascent microﬁbrils onto
microﬁbril proteins (Step 5).[13]. Since two of the three heparin-binding sites in rFBN1-C are
located adjacent to the N-to-C-terminal self-interaction site (see
Fig. 1A), it is conceivable that high afﬁnity heparin/heparan sulfate
interaction with the multimers sterically interferes with this self-
interaction at the bead stage. This provides a mechanistic explana-
tion why exogenously added heparin or heparan sulfate to cell cul-
tures prevents ﬁbrillin network formation [17,19]. We excluded in
cell culture an indirect inhibition through heparin-induced changes
of the available ﬁbronectin network, which has been previously
shown to be critical for microﬁbril formation [16,18].
The assembly of ﬁbrillins into microﬁbrils is a multistep and
complex process. In Fig. 4, we attempt to combine the experiments
presented here with previously published data into a reﬁned
model of microﬁbril assembly. After cleavage of the ﬁbrillin pro-
peptides (step 1), cell-associated multimerization into bead-like
structures occurs through the C-terminal domain (step 2) [13,33].
Multimerization of ﬁbrillins signiﬁcantly increases the apparent
afﬁnity to (i) heparin/heparan sulfate (shown here), (ii) the N-ter-
minus of ﬁbrillin-1 [13], and (iii) ﬁbronectin (shown in [16] and
quantiﬁed here). Based on the much higher apparent afﬁnities of
the ﬁbrillin beads to heparin/heparan sulfate compared to ﬁbro-
nectin, we propose that the beads ﬁrst interact with cell surface-
located heparan sulfate-containing proteoglycans (step 3). Based
on the very high afﬁnity of the densely packed ﬁbrillin C-termini,
it is more likely that this region interacts with cell surface-located
heparin/heparan sulfate compared to the less densely packed N-
termini, as others have suggested [26]. The positioning of beads
to the cell surface is supported by a recent study demonstrating
punctate cell surface-located ﬁbrillin-1 deposits in early assembly
[34]. Bax et al. observed that the heparin-binding ﬁbrillin-1 frag-
ments induced focal adhesions, suggesting that syndecans are
involved in ﬁbrillin-1-mediated focal adhesion formation [35].
Fibrillin-triggered focal adhesion formation and tension mediated
through intracellular actin ﬁlaments potentially serves to position
bead-like multimers in close vicinity (step 4). The high propensity
of multimeric beads to interact in an N-to-C-terminal fashion likely
generates the polarity of the ﬁbrillin molecules in nascent microﬁ-
brils. Eventually, these nascent microﬁbrils are transferred ontocleaved (Step 1), and the proteins assemble into multimers through their C-termini
e via C-terminal binding sites mediated by increased apparent afﬁnities upon
lly helps position the bead-like ﬁbrillin multimers in close vicinity to promote N-to-
ﬁbronectin ﬁbers for further stabilization, elongation and interaction with other
L. Sabatier et al. / FEBS Letters 588 (2014) 2890–2897 2897ﬁbronectin ﬁbers, which can act to stabilize growing microﬁbrils,
or potentially provide a template for elongation and interaction
with other microﬁbril proteins (step 5) [34,36].
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